Fig. 1A.

The outline of chemotherapy and allo-HSCT for acute-type ATL (case 2).

We describe the case of a 46-year-old woman who was diagnosed with atypical HAM at 5 months after allo-HSCT for acute-type ATL. She demonstrated CR of ATL after one cycle of modified LSG15 therapy, four cycles of mogamulizumab therapy, and three cycles of CHOP therapy. Allo-HSCT was performed by MAC consisting of TBI 12 Gy and CPA 120 mg/kg for the patient from an unrelated donor of the Japan Marrow Donor Program with one locus HLA mismatch in a DNA allele. The number of days from the last mogamulizumab administration to allo-HSCT was 140. The patient developed tremors at 3 months, anuresis at 4 months, and bilateral lower-limb paralysis at 5 months after allo-HSCT for ATL.